Difference between revisions of "Remdesivir"
(lede add) |
|||
| Line 4: | Line 4: | ||
|description=Expensive COVID drug of dubious efficacy against [[COVID-19]] promoted by [[Anthony Fauci]] and [[Gilead Sciences]]. | |description=Expensive COVID drug of dubious efficacy against [[COVID-19]] promoted by [[Anthony Fauci]] and [[Gilead Sciences]]. | ||
|constitutes=drug | |constitutes=drug | ||
| − | }}'''Remdesivir''' is a [[drug]] developed by [[Gilead Sciences]] and promoted by [[Anthony Fauci]] for [[COVID-19]], reportedly taken by [[Donald Trump]] in October 2020. | + | }}'''Remdesivir''' is a [[drug]] developed by [[Gilead Sciences]] and promoted by [[Anthony Fauci]] for [[COVID-19]], reportedly taken by [[Donald Trump]] in October 2020. It was the first FDA-approved drug for treatment of the virus,<ref>https://www.globalresearch.ca/very-bad-look-remdesivir-first-fda-approved-covid-19-drug/5728066</ref> although multiple studies have failed to show any statistically significant effect on fatality.<ref>https://www.zerohedge.com/geopolitical/massive-who-study-shows-remdesivir-doesnt-lower-covid-19-mortality</ref> Paul Marik, author of the EVMS Covid-19 Critical Care Protocol, called remdesivir a “particularly useless drug”.<ref>https://swprs.org/remdesivir-an-epidemic-failure/</ref> |
==Origins== | ==Origins== | ||
Revision as of 17:02, 30 October 2020
 Remdesivir(drug)   | |
|---|---|
 | |
| Interest of | Bryan Ardis |
| Expensive COVID drug of dubious efficacy against COVID-19 promoted by Anthony Fauci and Gilead Sciences. | |
Remdesivir is a drug developed by Gilead Sciences and promoted by Anthony Fauci for COVID-19, reportedly taken by Donald Trump in October 2020. It was the first FDA-approved drug for treatment of the virus,[1] although multiple studies have failed to show any statistically significant effect on fatality.[2] Paul Marik, author of the EVMS Covid-19 Critical Care Protocol, called remdesivir a “particularly useless drug”.[3]
Contents
Origins
The drug was developed with US government grants. Mint Press News quoted a figure of $70 million,[4] other estimates range as high as $6.5 billion.[5]
Efficacy
A study suggested that the drug did not affect the COVID case fatality rate, but reduced the average hospital visit for COVID-19 patients from 15 days to 11 days when compared to a placebo.[4] In July 2020 "There have been rising global concerns about the haste to rely on remdesivir before its efficacy is proven, particularly that the results of published trials show that it has no therapeutic benefits of statistical significance."[6]
Pricing
Developers Gilead faced criticism for charging $2,340 to $3,120 for a five day course of the drug.[4][5]
References
- ↑ https://www.globalresearch.ca/very-bad-look-remdesivir-first-fda-approved-covid-19-drug/5728066
- ↑ https://www.zerohedge.com/geopolitical/massive-who-study-shows-remdesivir-doesnt-lower-covid-19-mortality
- ↑ https://swprs.org/remdesivir-an-epidemic-failure/
- ↑ a b c https://www.mintpressnews.com/public-outcry-gilead-charges-3000-covid-19-drug-cost-pennies/269110/
- ↑ a b https://www.nakedcapitalism.com/2020/07/big-pharma-wants-to-pocket-the-profits-from-a-covid-treatment-you-already-paid-for.html
- ↑ https://twn.my/title2/unsd/2020/unsd200708.htm
